Greece is going bankrupt. The euro is shaky. The oil inundating the Gulf Coast may eliminate one-third of the US seafood catch. In the midst of this chaos, the nightly news focuses on a medical breakthrough. At a cost of about $100 000, a man with metastatic prostate cancer can be treated with an infusion of his own cells and live, on average, a few months longer....
The remainder of this op-ed can be found at jama.ama-assn.org
JAMA. 2010;304(4):465-466.
This commentary originally appeared in The Journal of the American Medical Association on July 28, 2010. Commentary gives RAND researchers a platform to convey insights based on their professional expertise and often on their peer-reviewed research and analysis.